Consequently, clinicians are more frequently confronted with the context of headache disorders.17These medications are often highly regarded by patients for their striking benefits, not only in terms of weight reduction but also of improving associated comorbidities such as hypertension, diabetes, depression, and anxiety.11This raises a timely clinical question: Could GLP-1 RAs represent a therapeutic strategy for obese patients with migraine or other headaches who also struggle with weight management?22. This evidence concerns the gene GLP1R and depressive symptom measurement.